<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="219814">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00222352</url>
  </required_header>
  <id_info>
    <org_study_id>TJH 0428</org_study_id>
    <nct_id>NCT00222352</nct_id>
  </id_info>
  <brief_title>Diagnosis and Treatment of ACS in the ED: The Impact of Rapid Bedside cTnI Testing on Outcomes</brief_title>
  <official_title>Diagnosis and Treatment of Acute Coronary Syndromes in the Emergency Department: The Impact of Rapid Bedside cTnI Testing on Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Emergency Physicians</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Point of Care</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jewish Hospital, Cincinnati, Ohio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Emergency Physicians</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomized, controlled clinical trial, point-of care testing at the bedside using the
      cardiac biomarker troponin I in ED patients with possible ACS will be compared to
      traditional testing of this assay for myocardial necrosis obtained in the central
      laboratory. Our hypothesis: point-of-care testing for troponin I will decrease the time for
      disposition of patients with possible ACS in the emergency setting and decrease the time
      required for administering appropriate therapies for these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac troponin I is routinely used in the emergency department as a risk stratification
      tool for detecting myocardial necrosis in patients with possible acute coronary syndrome. It
      is our hypothesis that having bedside, point-of-care testing for TnI in the ED will decrease
      time needed to disposition patients to home from the ED or send to the cardiac
      catheterization laboratory or intensive care setting. Similarly, having point-of-care
      testing in the ED should decrease the time required to deliver anti-platelet drugs such as
      aspirin and glycoprotein IIb/IIIa inhibitors and anti-thrombin agents such as heparin to
      high risk patients found to have a positive TnI test. This will be evaluated in a
      randomized, controlled clinical trial of 2000 patients. Half will have the test performed in
      the ED at the bedside (point-of-care) while the other half will receive the usual lab
      results obtained from the central lab (typically requiring 1.5-2 hours to return).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <completion_date>December 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Natural History</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment>2000</enrollment>
  <condition>Angina, Unstable</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 21 years old

          -  Chest pain or other symptoms that lead to drawing cardiac bio-markers for possible
             ACS diagnosis

        Exclusion Criteria:

          -  Presentation with chest pain in the presence of a tachydysrhythmia (ventricular
             tachycardia, supraventricular tachycardia, or rapid atrial fibrillation)

          -  Presentation with ECG diagnostic for STEMI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter B Gibler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>EMCREG International; University Emergency Physicians, Inc; University of Cincinnati College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-6203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jewish Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.emcreg.org</url>
    <description>EMCREG International Website</description>
  </link>
  <verification_date>February 2007</verification_date>
  <lastchanged_date>February 27, 2007</lastchanged_date>
  <firstreceived_date>September 14, 2005</firstreceived_date>
  <keyword>Unstable Angina</keyword>
  <keyword>Non-ST-segment Myocardial Infarction</keyword>
  <keyword>Myocardial Necrosis</keyword>
  <keyword>Troponin I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
